A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis
This study involves chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their disease. In autoimmune diseases such as rheumatoid arthritis (RA), certain parts of th
Why this Research Matters
What happens at the study visits? Screening: You will receive screening health assessments to confirm if you qualify to join the trial. You will answer questions about your medical history, symptoms, and current medications. Joint Biopsy: You will have
Who can Participate
To be eligible for this study a participant must meet all the following criteria: - Age 18-70 years - Diagnosis of moderate to severe rheumatoid arthritis (RA) that is not well managed by current medications - Have tried and failed to respond to medicat - Have tried and failed to respond to at least 3 biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for the treatment of RA, which includes but is not limited to Humira, Enbrel, Simponi, Remicade, Actemra, Kevzara, Orencia, Ritux
Study ID
Protocol Number: 22-1945
Meet the Team
Principal Investigator